The "5-HT2A Agonist -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
5-HT2A Agonist - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT2A Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Descriptive coverage of pipeline development activities for 5-HT2A Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active 5-HT2A Agonist pipeline products by developmental stage, product type, molecule type, and administration route.
Scope of the report
- Provides a snapshot of the therapeutics pipeline activity for 5-HT2A Agonist
- Features the 5-HT2A Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages
- Offers detailed therapeutic product profiles of 5-HT2A Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across 5-HT2A Agonist
Key Topics Covered:
1. Report Introduction
2. 5-HT2A Agonist - Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for 5-HT2A Agonist
4. Comparative Analysis
5. 5-HT2A Agonist Pipeline Products in Clinical Stages
- Product Description
- Research and Development
- Product Development Activities
6. 5-HT2A Agonist Pipeline Products in Non-clinical Stages
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment: Active Products
- Pipeline Assessment by Route of Administration
- Pipeline Assessment by Stage and Route of Administration
- Pipeline Assessment by Molecule Type
- Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
- Product Description
- Research and Development
- Product Development Activities
-
Reason for dormancy/discontinuation
Companies Mentioned
- Reviva Pharmaceuticals
- Carlsson Research AB
- Nelotanserin
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5swfz6
View source version on businesswire.com: https://www.businesswire.com/news/home/20190409005578/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.